Transcranial Direct Current Stimulation for the Management of Neuropathic Pain: A Narrative Review

Yang, Seoyon; Chang, Min Cheol

doi:10.36076/ppj.2021.24.e771

Cited by 13 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuropathic pain is a chronic pain type which is often resistant to available analgesics [20][21][22] and therefore, much effort is made to find novel methods to cope with this serious clinical issue. In this context, there is a strong need for new analgesic drug candidates able to attenuate the main symptoms of neuropathic pain, i.e., mechanical and thermal hypersensitivity resulting in tactile and thermal allodynia and hyperalgesia [23,24].…”

Section: Discussionmentioning

confidence: 99%

Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice

Sałat,

Zaręba,

Awtoniuk

et al. 2023

Molecules

View full text Add to dashboard Cite

Background: Neuropathic pain is drug-resistant to available analgesics and therefore novel treatment options for this debilitating clinical condition are urgently needed. Recently, two drug candidates, namely mirogabalin and cebranopadol have become a subject of interest because of their potential utility as analgesics for chronic pain treatment. However, they have not been investigated thoroughly in some types of neuropathic pain, both in humans and experimental animals. Methods: This study used the von Frey test, the hot plate test and the two-plate thermal place preference test supported by image analysis and machine learning to assess the effect of intraperitoneal mirogabalin and subcutaneous cebranopadol on mechanical and thermal nociceptive threshold in mouse models of neuropathic pain induced by streptozotocin, paclitaxel and oxaliplatin. Results: Mirogabalin and cebranopadol effectively attenuated tactile allodynia in models of neuropathic pain induced by streptozotocin and paclitaxel. Cebranopadol was more effective than mirogabalin in this respect. Both drugs also elevated the heat nociceptive threshold in mice. In the oxaliplatin model, cebranopadol and mirogabalin reduced cold-exacerbated pain. Conclusions: Since mirogabalin and cebranopadol are effective in animal models of neuropathic pain, they seem to be promising novel therapies for various types of neuropathic pain in patients, in particular those who are resistant to available analgesics.

show abstract

Section: Discussionmentioning

confidence: 99%

Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice

Sałat,

Zaręba,

Awtoniuk

et al. 2023

Molecules

View full text Add to dashboard Cite

show abstract

“…Unlike DBS, tDCS is a non-invasive technique of brain stimulation to regulate neuronal activity in the motor cortex. tDCS has been shown to mitigate neuropathic pain in patients with SCI ( Yang and Chang, 2021 ). tDCS with rehabilitation training augmented adaptive plasticity and promoted recovery of upper limb function in participants with incomplete tetraplegia ( Potter-Baker et al, 2017 ).…”

Section: Therapeutic Strategies For Spinal Cord Repairmentioning

confidence: 99%

Recent progress and challenges in the treatment of spinal cord injury

2023

View full text Add to dashboard Cite

Spinal cord injury (SCI) disrupts the structural and functional connectivity between the higher centre and the spinal cord, resulting in severe motor, sensory, and autonomic dysfunction with a variety of complications. The pathophysiology of SCI is complicated and multifaceted, and thus individual treatments acting on a specific aspect or process are inadequate to elicit neuronal regeneration and functional recovery after SCI. Combinatory strategies targeting multiple aspects of SCI pathology have achieved greater beneficial effects than individual therapy alone. Although many problems and challenges remain, the encouraging outcomes that have been achieved in preclinical models offer a promising foothold for the development of novel clinical strategies to treat SCI. In this review, we characterize the mechanisms underlying axon regeneration of adult neurons and summarize recent advances in facilitating functional recovery following SCI at both the acute and chronic stages. In addition, we analyze the current status, remaining problems, and realistic challenges towards clinical translation. Finally, we consider the future of SCI treatment and provide insights into how to narrow the translational gap that currently exists between preclinical studies and clinical practice. Going forward, clinical trials should emphasize multidisciplinary conversation and cooperation to identify optimal combinatorial approaches to maximize therapeutic benefit in humans with SCI.

show abstract

“…One tDCS technique has shown beneficial outcomes in alleviating neuropathic pain associated with traumatic spinal cord injury, stroke, multiple sclerosis, fibromyalgia, trigeminal neuralgia and diabetes [ 198 ]. A randomized controlled trial conducted by Straudi et al showed significantly reduced pain and increased psychological well-being after the use of tDCS in patients with chronic low back pain compared with a sham-tDCS group [ 219 ].…”

Section: Treatment Strategies For Neuropathic Painmentioning

confidence: 99%

Diagnosis and Management of Neuropathic Pain in Spine Diseases

Bielewicz

Kamieniak

Szymoniuk

et al. 2023

JCM

View full text Add to dashboard Cite

Neuropathic pain is generally defined as a non-physiological pain experience caused by damage to the nervous system. It can occur spontaneously, as a reaction to a given stimulus, or independently of its action, leading to unusual pain sensations usually referred to as firing, burning or throbbing. In the course of spine disorders, pain symptoms commonly occur. According to available epidemiological studies, a neuropathic component of pain is often present in patients with spinal diseases, with a frequency ranging from 36% to 55% of patients. Distinguishing between chronic nociceptive pain and neuropathic pain very often remains a challenge. Consequently, neuropathic pain is often underdiagnosed in patients with spinal diseases. In reference to current guidelines for the treatment of neuropathic pain, gabapentin, serotonin and norepinephrine reuptake inhibitors and tricyclic antidepressants constitute first-line therapeutic agents. However, long-term pharmacologic treatment often leads to developing tolerance and resistance to used medications. Therefore, in recent years, a plethora of therapeutic methods for neuropathic pain have been developed and investigated to improve clinical outcomes. In this review, we briefly summarized current knowledge about the pathophysiology and diagnosis of neuropathic pain. Moreover, we described the most effective treatment approaches for neuropathic pain and discussed their relevance in the treatment of spinal pain.

show abstract

Transcranial Direct Current Stimulation for the Management of Neuropathic Pain: A Narrative Review

Cited by 13 publications

References 29 publications

Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice

Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice

Recent progress and challenges in the treatment of spinal cord injury

Diagnosis and Management of Neuropathic Pain in Spine Diseases

Contact Info

Product

Resources

About